Earnings Feed
Start Free
Shattuck Labs, Inc.·4

Jun 9, 8:56 PM ET

Ashiya Mona 4

Research Summary

AI-generated summary

Updated

Shattuck Labs (STTK) Director Ashiya Mona Converts Warrants

What Happened

  • Ashiya Mona, a director of Shattuck Labs, reported conversions of derivative securities on June 8, 2026. The filing shows acquisitions of 15,366,490 and 3,073,298 derivative units and matching dispositions of the same amounts — a total of 18,439,788 derivative securities converted. No purchase or sale price is reported (N/A) and no immediate common-stock sale or cash consideration is shown. Footnotes state this reflects the exercise/conversion of Common Warrants into Pre‑Funded Warrants in a private-placement transaction.

Key Details

  • Date of transactions: June 8, 2026; Form 4 filed June 9, 2026 (timely).
  • Reported amounts: 15,366,490 and 3,073,298 derivative securities acquired and the same amounts disposed (total 18,439,788).
  • Price/consideration: N/A (no dollar amounts reported).
  • Net change in common shares reported on this filing: 0 (these were conversions of derivative instruments, not open‑market buys/sells of common stock).
  • Shares owned after the transaction: not specified in the filing.
  • Notable footnotes:
    • The conversions relate to a private placement with OrbiMed funds (Common Warrants exchanged for Pre‑Funded Warrants).
    • Pre‑Funded Warrants are exercisable any time but subject to a 9.99% beneficial‑ownership blocker; Common Warrants had an expiration tied to clinical‑trial data timing.
    • Securities are held of record by OrbiMed funds; OrbiMed Advisors and related GP entities may be deemed to have voting/investment power but disclaim beneficial ownership except for any pecuniary interest.

Context

  • These are derivative conversions (warrant exchanges), not standard market purchases or sales of common stock. Converting Common Warrants into Pre‑Funded Warrants changes the type of instrument held and may enable future exercise into common shares, but this filing shows no immediate issuance or sale of common stock.
  • The reporting involves institutional OrbiMed entities and contains disclaimers that the filing parties do not assert beneficial ownership beyond any pecuniary interest.